Select a community
Parkinson's
Find out more about the PatientsLikeMe
Parkinson's Community
Home > Community Treatment Reports > Fexofenadine Treatment Report

See More Treatments

See all treatments in the PatientsLikeMe system shared by patients just like you.


Fexofenadine Treatment Report

Brand Names: Allegra

What is Fexofenadine? Fexofenadine is an allergy medicine taken for seasonal allergies and hives, to relieve symptoms like itchy eyes, runny nose, and sneezing. Unlike some other allergy medication fexofenadine does not cause drowsiness and driving is not contraindicated.

See more information, including instructions, precautions, side effects, and interactions.


Reasons taken

6 patients in the community are taking or have taken Fexofenadine.

Reason # Patients Percentage of patients
Allergies 4 66%
Other 2 33%

Dosages

Based on the patients currently taking Fexofenadine.

  180mg as needed 60 mg daily 180 mg daily
  1 Number of Patients: 1 1 Number of Patients: 1 4 Number of Patients: 4  

Duration

How long current patients have been taking Fexofenadine or how long patients were taking Fexofenadine before stopping.

Currently Taking Fexofenadine

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
1
0
0
0
5

Patient Reported Evaluations

Results from 2 patient evaluations. See the overall results and all individual evaluations.

Efficacy (Effect based on reason taken)

Major 50% 1
Moderate 50% 1

Other

Side-effects (as an overall problem)

Severe 0% 0
Moderate 0% 0
Mild 0% 0
None 100% 2

Top reported side-effects include: Jittery feeling, Dryness, Fogginess

Summary results are based on 2 individual responses. For more information, see overall results for Adherence, Burden and Cost.

Individual Patient Reported Evaluations (1 of 2)

  • Dirty Butter
    Sex: F
    Mouth/throat: none
    Arms: mild
    Chest: none
    Legs: mild
  • Dirty Butter
  • by Dirty Butter
    Sep 11, 2008
  • EfficacyMajor
  • Side-effectsNone
  • Other

See all evaluation results for Fexofenadine

Report created on November 08, 2009.